Quantcast

Industry news that matters to you.  Learn more

Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

Protagen Signs Collaboration with QIAGEN to Develop Novel Protein-Based Companion Diagnostics for Autoimmune Therapies

Protagen AG recently announced that it has entered into a long-term collaboration agreement with QIAGEN targeting the development of novel protein-based companion diagnostics for autoimmune disorders. Under the terms of the agreement, QIAGEN will gain access to the proprietary SeroTag® technology platform of Protagen, which enables the discovery and validation of novel protein-based marker panels. Such markers hold great promise for the development into companion diagnostics to guide treatment decisions in various autoimmune disorders. Financial details of the collaboration were not disclosed.

QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced it has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.

QIAGEN Announces Broad Agreement With Astellas Pharma to Develop Companion Diagnostics

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced a master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications or biomarkers, thereby giving Astellas access to QIAGEN’s development capabilities for assays based on PCR, NGS and multi-modal testing technologies using liquid and tissue biopsies. Two initial projects in the collaboration focus on oncology and aim to pair QIAGEN diagnostics with Astellas compounds in early-stage clinical trials: ASP5878, a fibroblast growth factor receptor (FGFR) inhibitor, and ASP8273, an EGFR inhibitor. Financial terms were not disclosed.

CirQuest Labs Expands Molecular Oncology and Companion Testing Services CirQuest Oncology Division

CirQuest Labs (Memphis, TN) announces a substantial advance in the specialized laboratory services area. Expanding upon its established skills in cardiovascular disease and immunohematology, CirQuest now provides the latest techniques in oncology research and development and extensive companion testing in the clinical oncology field.